Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report)’s stock price rose 16.3% during trading on Thursday . The company traded as high as $5.45 and last traded at $2.50. Approximately 470 shares changed hands during trading, a decline of 68% from the average daily volume of 1,459 shares. The stock had previously closed at $2.15.
Silence Therapeutics Trading Up 16.3 %
The stock’s 50-day simple moving average is $5.71 and its 200-day simple moving average is $6.47.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Read More
- Five stocks we like better than Silence Therapeutics
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- 3 Fintech Stocks With Good 2021 Prospects
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Stock Dividend Cuts Happen Are You Ready?
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
